Based on these findings, LATIFY (NCT05450692) is an ongoing phase III, open-label, randomized, multicenter trial evaluating the efficacy and safety of ceralasertib plus durvalumab versus docetaxel in patients with locally advanced or metastatic NSCLC who have progressed after anti–PD-(L)1 therapy and a platinum-based doublet. This evidence concerns the gene CD274 and non-small cell lung carcinoma.